Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of B-cell lymphoma
No previous systemic treatment for lymphoma
Subject demonstrates need for treatment for lymphoma
Ann-Arbor Stage 2 (noncontiguous), 3, or 4 disease
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy
Adequate performance status
Required baseline laboratory data within protocol-specified parameters
You may not be if
Known history of transformed lymphoma or diffuse large cell lymphoid malignancy
Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Known history of drug-induced liver injury, chronic active hepatitis B (HBV), chronic active hepatitis C (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis
Ongoing inflammatory bowel disease
Known human immunodeficiency virus (HIV) infection
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
Ongoing immunosuppressive therapy, including systemic corticosteroids (\> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for autoimmune anemia and/or thrombocytopenia
Clareo Health | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
